November 14, 2023 | [Read Online]( Good Afternoon! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Today is Tuesday, November 14th. I hope you have a great day in the market. Now, let's get ready to trade! Markets ð Stocks stumbled out of the gate on Monday, and most large-cap Indexed ended the day close to flat. The S&P 500 lost less than 0.1%, while the Nasdaq edged lower by 0.2%. The Dow added 0.1% on the session, and the Russell 2K ended the day even. Today, futures are in a holding pattern ahead of this morningâs CPI report. S&P 500 contracts are currently flat. Sponsored [[ALERT] A Fast-Moving Trade Opportunity](ð¨ Weâve been monitoring this tiny, overlooked stock for weeks, and now weâre sharing it with the public for the first time. This company has been on our radar since earlier this month, when shares began to rebound. Now, itâs up over 19.6% over the past 10 days. But now, this rally could be preparing to go into overdrive after a breakout earnings report this morning. This tiny company reported a record-breaking Q3 revenues & double-digit sales growth, and it slashed its margins by nearly a third! This one could move fast at the open, so donât wait! Make your move before you miss out. [See the Ticker on the Next Page »]( Premarket Highlights ð ð¡ October CPI Preview: Inflation's Temperature Check Grab your coffee and calculators, folks! The Labor Department's about to drop the latest CPI (Consumer Price Index) stats, and let's just say, it's like the financial world's version of waiting for the season finale cliffhanger to resolve. ð Economist Place Your Bets! - Monthly CPI Rise: Economists are betting on a modest 0.1% hop from September. Not exactly a high jump, but hey, every little bit counts. - Yearly CPI Surge: Compared to last October, they're eyeing a 3.3% jump. Inflation's playing the long game here. - Core CPI (Sans Drama): Stripping out the ever-dramatic food and energy prices, core CPI is expected to strut up by 4.1% from last year. Looks like the core's got more in store. ð Key Takeaways Inflation's been the big bad wolf huffing and puffing at our economic doors. These numbers aren't just digits; they're like the economy's pulse rate. High, low, or just right â it's what keeps the Fed and market watchers up at night. As we await the grand reveal, remember: whether it's trick or treat with these CPI numbers, it's always a rollercoaster in the land of economics. Stay tuned, stay informed, and maybe keep a brown paper bag handy â just in case of hyperventilation! What to Watch Today ð New Inflation Data Octoberâs CPI report is undoubtedly the biggest item on todayâs calendar. Traders will be looking closely for any trouble spots that could encourage the Fed to impose another rate hike. Keep an eye on this report because it will likely set the tone for the trading session. Major Earnings ð° - Home Depot (The) [HD] ⦠AM - Amgen [AMGN] ... AM - Caterpillar [CAT] ... AM - Eaton Corporation [ETN] ... AM - Enterprise Products Partners [EPD] ... AM - Marathon Petroleum Corporation [MPC] ... AM - Ecolab [ECL] ... AM - MSCI [MSCI] ... AM - Advanced Micro Devices [AMD] ...PM - Oneok [OKE] ... PM Economy ð - NFIB optimism index [Oct] ... 6:00a - Consumer price index [Oct] ... 8:30a - Core CPI [Oct] ⦠8:30a Running Hot ð¥ Decliners - Beauty Health [SKIN] >> (53.0%) - Kubient [KBNT] >> (46.9%) - Trivago [TRVG] >> (46.7%) Gainers - INVO Bioscience [INVO] >> +31.6% - ProKidney [PROK] >> +14.3% - Aluanos Therapeutics [TCRT] >> +15.9% reAlpha Tech [AIRE] - Last Close: $5.89 reAlpha Tech is rebounding suddenly after a long slide. The residential real estate firm skyrocketed in its Oct. 23rd IPO, but the party was short-lived, and shares began pulling back the very next day. However, the slide seems to be drawing to a close after the stock suddenly jumped 33.8% on Monday. It was the stockâs first daily gain since its IPO several weeks ago, and it was accompanied by a tremendous spike in trading volume. The rally is continuing in todayâs premarket. AIRE is up 81.1%, and itâs one of this morningâs top stocks. My Take: Thereâs no company-specific news to back up this rally, but it looks like AIREâs slide could be bottoming out, at least from a technical analysis standpoint, and the accompanying volume spike could be a promising sign. Celebrite DI [CLBT] - Last Close: $7.54 Israeli tech firm Celebrite is ralling after a strong earnings report. The investigative software company reported better-than-expected Q3 earnings early this morning, and shares are rallying in response. Celebrite DI reported EPS of $0.09 per diluted share, marking a significant spike from last yearâs $0.01 EPS, and topping the consensus of $0.05 per share. Revenues of $84.2 million were up 17.4% YoY and also topped the Streetâs $82.1 million consensus estimate. Celbrite also raised its full-year revenue guidance to account for the strong quarter. CLBT is one of this morningâs top stocks with a 13.9% gain. My Take: CLBTâs numbers look great, and itâs recent technical performance also has promise. Shares are on pace to breakthrough a key resistance point at $8 per share, and it could find new price support at this level, if it can hold on. Theseus Pharma [THRX] - Last Close: $2.14 The buyout bulls are descending on Theseus Pharma. The tiny pharma firm is getting a big boost after announcing plans to explore strategic alternatives for the company. Theseus Pharma has been on the struggle bus lately. Shares are down 79.7% over the past six months, with no sign of relief in sight. However, shares are rallying after the companyâs announcement, and it could provide to be a pivot point for Theseus Pharma. THRX is one of this morningâs hottest stocks, with a 39.7% gain. My Take: THRX isnât out of the frying pan yet. This rally will be short-lived if it doesnât keep investors on the hook. If it doesnât make progress on a deal soon, the market could quickly lose interest in this micro-cap biotech. BioCardia [BCDA] - Last Close: $0.3990 BioCardia is skyrocketing after landing a key regulatory approval. This morning, the company revealed that the FDA approved its Phase III trial design for its CariAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP Heart Failure trial has completed enrollment, and it is anticipated that the final data analyses will be reported in Q4 2024. The FDA has approved the proposed CardiAMP Heart Failure II study, including a requirement that patients demonstrate a prerquisite baseline. CEO Peter Altman said, âWe expect that we can perform this study efficiently at world class clinical centers based on the extensive experience of the ongoing trial and its positive clinical outcomes.â BCDA is todayâs top mover with a 146.6% gain on elevated trading volume in response to the news. My Take: The market appears to be pretty excited about the BCDA trial, but only time will tell if itâs a success. Until then, this tiny stock could be very volatile. That's it for today! Thanks for reading, and good luck out there! Best Regards, â Chris D.
Elite Trade Club P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Sign up for SMS]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2023 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247
Orlando, Florida 32828, United States of America